MARINUS PHARMACEUTICALS,INC. (NASDAQ:MRNS) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
Marinus Pharmaceuticals, Inc. (the Company) issued a press
release on March 13, 2017 announcing its financial results for
the year ended December 31, 2016.A copy of the press release is
being furnished to the Securities and Exchange Commission as
Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated by reference to this Item2.02.
The information furnished to this Item2.02 shall not be deemed to
be filed for purposes of Section18 of the Securities Exchange Act
of 1934 (the Exchange Act) or otherwise subject to the
liabilities of that section, nor shall it be deemed to be
incorporated by reference into any of the Companys filings with
the Securities and Exchange Commission under the Exchange Act or
the Securities Act of 1933, whether made before or after the date
hereof, regardless of any general incorporation language in such
a filing, except as expressly set forth by specific reference in
such a filing. Except as required by law, we undertake no duty or
obligation to publicly update or revise the information so
furnished.
Item 9.01. Financial Statements and Exhibits.
|
(d) |
Exhibits |
|
Exhibit No. |
Description |
|
99.1 |
Press Release, dated March 13, 2017, of Marinus |
2
About MARINUS PHARMACEUTICALS, INC. (NASDAQ:MRNS)
Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy. MARINUS PHARMACEUTICALS, INC. (NASDAQ:MRNS) Recent Trading Information
MARINUS PHARMACEUTICALS, INC. (NASDAQ:MRNS) closed its last trading session up +0.08 at 1.53 with 541,114 shares trading hands.